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ABSTRACT: Background: Outcomes are un-
predictable for neurological presentations of Wilson’s
disease (WD). Dosing regimens for chelation therapy
vary and monitoring depends on copper indices,
which do not reflect end-organ damage.
Objective: To identify a biomarker for neurological
involvement in WD.
Methods: Neuronal and glial-specific proteins were
measured in plasma samples from 40 patients and
38 age-matched controls. Patients were divided into
neurological or hepatic presentations and those with
recent neurological presentations or deterioration asso-
ciated with non-adherence were subcategorized as
having active neurological disease. Unified WD Rating
Scale scores and copper indices were recorded.
Results: Unlike copper indices, neurofilament light
(NfL) concentrations were higher in neurological than
hepatic presentations. They were also higher in those
with active neurological disease when controlling for
severity and correlated with neurological examination
subscores in stable patients.
Conclusion: NfL is a biomarker of neurological involve-
ment with potential use in guiding chelation therapy and
clinical trials for novel treatments. © 2020 University
College London. Movement Disorders published by
Wiley Periodicals LLC on behalf of International
Parkinson and Movement Disorder Society
Key Words: Wilson’s disease; biomarkers; neu-
rofilament light
Introduction
Wilson’s disease (WD) is an autosomal-recessive dis-
order of copper metabolism with an estimated disease
prevalence of 1 in 30,000.1 A movement disorder char-
acterized by tremor, dystonia, parkinsonism, or a com-
bination of these develops in those with neurological
involvement, and psychiatric manifestations are also
common.2 Presentations with neurological or psychiat-
ric features are therefore classified as “neurological”
whereas those with liver disease alone are classified as
“hepatic”.3
Chelating agents prevent disease progression in the
majority, and reduce neurological symptoms in some,
but dosing regimens vary and these treatments can
cause debilitating adverse effects and paradoxical wors-
ening.4,5 Monitoring involves measuring 24-hr urinary
copper output and calculating serum non-ceruloplas-
min-bound copper.5 While consensus guidelines pro-
vide target ranges, these indices are method-dependent
and vary between individuals.6,7 Moreover, there is no
association between 24-hr urinary copper output or
serum non-ceruloplasmin copper and neurological
severity at presentation.2 Biomarkers of end-organ
damage are needed to improve neurological outcomes
with chelation therapy and prepare for clinical trials of
novel treatment strategies, such as gene therapy.8
Several neuronal or glial-specific proteins are emerg-
ing as candidate biomarkers for other neurological dis-
eases.9 Neurofilament light (NfL), also referred to as
neurofilament light chain, is a cytoskeletal filament
released during neuroaxonal injury that can be mea-
sured at low concentrations in plasma using single mol-
ecule array technology. Potential utility as a biomarker
has been demonstrated in various neurodegenerative
diseases.10,11 In multiple sclerosis, serum concentrations
are independently associated with clinical severity and
disease status and reduce with escalation of disease-
modifying therapy.9 Tau, a microtubule-stabilising pro-
tein, glial fibrillary acidic protein (GFAP), an intermedi-
ate filament, and ubiquitin carboxyl-terminal hydrolase
L1 (UCH-L1), a cytoplasmic enzyme, can also be mea-
sured using similar methods.
These candidate biomarkers have not been studied in
WD, with one exception: Lekomtseva and colleagues
demonstrated that serum tau measured using an enzyme-
linked immunosorbent assay (ELISA) was higher in neu-
rological presentations than controls but the relationship
with neurological involvement was untested.12 We
hypothesized that neuronal and glial-specific proteins dif-
ferentiate neurological from hepatic presentations, and
indicate the severity of neurological involvement.
Patients and Methods
Study Design
We recruited 40 participants to a prospective study on
WD. Consecutive patients attending neurology, hepato-
logy, and metabolic outpatient clinics at the National
Hospital for Neurology and Neurosurgery (NHNN) and
Royal Free Hospital were invited to participate. Members
of the WD Support Group UK research register were also
sent an invitation letter via post. We included patients
aged 16 years or over with diagnoses based on the Leip-
zig criteria.3 Exclusion criteria were any unrelated medi-
cal or psychiatric illness that would interfere with
completing assessments and pregnancy.
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Participants attended a baseline visit at NHNN for
clinical assessments and venepuncture between January
and December 2019. We used interviews during visits
and subsequent review of records, where necessary, to
confirm each participant’s presentation at the time of
their diagnosis using the international consensus on the
phenotypic classification of WD3: those who had initially
presented with neurological or psychiatric symptoms
were classified as neurological presentations (n = 23).
Those without were classified as hepatic presentations
(n = 17), including asymptomatic individuals identified
through family screening with previously abnormal liver
function tests or hepatic imaging (n = 6).
We also subcategorized patients based on their recent
neurological status. Those with a neurological presenta-
tion (n = 2), or a documented deterioration in neurolog-
ical function related to non-adherence (n = 3), in the
preceding 6 months were considered to have active, as
opposed to stable, neurological disease. We did not
subcategorize patients according to their hepatic status.
Plasma samples from 38 age-matched healthy con-
trols were provided from the Genetic Frontotemporal
Dementia Initiative cohort.13 These were family mem-
bers of patients with MAPT, GRN, and C9orf72 muta-
tions who had all undergone genetic testing and were
non-carriers.
The local ethics committees at each site approved the
study and all participants provided written informed
consent.
Procedures
A neurologist performed the Unified Wilson’s Disease
Rating Scale (UWDRS), a validated tool that includes
components of the Unified Parkinson’s Disease Rating
Scale and Burke–Fahn–Marsden Dystonia Rating Scale,
among others.14 Subscores for the neurological exami-
nation (UWDRS-N, 18-item), psychiatric assessment
(UWDRS-P, 19-item), and functional impairment
(UWDRS-F, 9-item) were recorded. A neuro-
ophthalmologist performed slit lamp examination to
assess for Kayser–Fleischer (KF) rings.
Plasma samples from EDTA tubes were processed
and stored at −80C using the same standardized pro-
cedure for both patients and controls. NfL, tau, UCH-
L1, and GFAP concentrations were measured using
Neurology 4-Plex A kits on a Simoa HD-X analyser
(Quanterix, Billerica, MA, USA).
Serum ceruloplasmin and copper were determined
using the immuno-turbidimetric test (Beckman Coulter,
Brea, CA, USA) and ICP-MS (NexION
300, PerkinElmer, Waltham, MA, USA), respectively,
and non-ceruloplasmin copper (NCC) was calculated.5
Exchangeable copper (CuEXC), a labile fraction of
serum copper bound to albumin and other peptides,
was measured.15 Blood samples were centrifuged and
stored at 4C overnight. Equal volumes of EDTA 3 g/L
were added to serum for 1 hr before ultrafiltration.
Copper was measured in filtrates as above. Urinary
copper output (UCu) was measured in 24-hr collections
while continuing medication. Aliquots were stored at
−20C before ICP-MS (7700x system, Agilent, Santa
Clara, CA, USA). Results from participants on zinc
therapy or with liver transplants, in whom UCu is
inherently lower, were excluded.
Statistical Analysis
We compared biomarkers and copper indices
between the neurological, hepatic, and control groups
using linear regression with age as a covariate, given
NfL increases with age.9 We used receiver operating
characteristic (ROC) curves to assess diagnostic perfor-
mance in differentiating groups and calculated sensitivi-
ties and cut-off values at 70%, 80%, and 90%
specificities where the area under the curve (AUC) was
increased (P < 0.05). We compared results between
active and stable patients using linear regression with
age and UWDRS-N as covariates. We assessed associa-
tions between biomarkers, copper indices, and UWDRS
subscores in stable patients using linear regression with
age as a covariate and corrected for multiple testing
using false discovery rate correction. We compared age
and disease duration between patients and controls
using unpaired t tests and assessed their association
with biomarkers using Spearman’s rank correlation
coefficient. We used R3.6.0 for statistical analysis and
GraphPad Prism 7 for graphs.
Results
Group demographic and clinical characteristics are
summarised in Table 1. The most frequent examination
findings in patients with neurological presentations
were impaired finger taps (item 15, 87%), leg agility
(item 20, 83%), arm and hand dystonia (item
23, 83%), oromandibular dystonia (item 11A, 78%),
rapid alternating movements (item 16, 74%), handwrit-
ing (item 17, 74%), and speech (item 10, 70%).
There were no differences in copper indices between
neurological and hepatic groups whereas NfL was higher
in the neurological than hepatic and control groups.
Copper indices and biomarker results are described in
Table 1 and group differences and the ROC curve for
NfL are depicted in Figure 1. The AUC for NfL in differ-
entiating neurological and hepatic patients was 0.707
(P = 0.028). For 70%, 80%, and 90% specificities, the
sensitivities were 61% (41–78%), 48% (29–67%), and
39% (22–59%) with cut-off values of 8.4, 9.7, and
12.9 ng/L, respectively. UCH-L1 was higher in neurolog-
ical compared to control but not hepatic groups. There
were no other group differences for other biomarkers.
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NfL was higher in active compared to stable patients
when controlling for neurological severity (22.2
vs 7.7 ng/L, P = 0.048), as was UCu (16.1 vs. 4.0 μmol,
P < 0.001). The highest NfL concentration (38.5 ng/L)
and UWDRS-N subscore (106) were in a newly-
diagnosed neurological patient with ongoing paradoxi-
cal worsening after starting penicillamine.
Associations between biomarkers, copper indices,
and UWDRS subscores in stable patients are shown in
Table S1. NfL was associated with UWDRS-N sub-
scores (β = 0.1, P = 0.003), tau was associated with
UWDRS-N (β = 0.02, P < 0.001) and UWDRS-F
(β = 0.06, P < 0.001) subscores, and UCH-L1 was asso-
ciated with UWDRS-N (β = 0.95, P < 0.001) and
UWDRS-F (β = 2.70, P < 0.001) subscores. These asso-
ciations persisted after correction for multiple testing.
NfL concentrations were also correlated with NCC
(β = 0.93, P = 0.04) but this association did not persist
after correction for multiple testing.
NfL increased with age in controls (ρ = 0.74,
P < 0.001) as expected, and there was no association
between NfL and disease duration (ρ = 0.29, P = 0.10).
Discussion
We report differences in plasma NfL concentrations
between neurological and hepatic presentations in a
cohort of predominantly chronically-treated WD
patients. NfL and UCu were higher in the small number
of cases with active neurological disease (after control-
ling for severity); however, UCu, like other copper indi-
ces, did not differ according to presentation.
The association of NfL with UWDRS-N in stable
patients adds further support for NfL as a potential bio-
marker of neurological involvement. It suggests that some
participants had ongoing neuroaxonal injury despite treat-
ment. We hypothesise that our definition of active disease
might be too strict or some stable patients may have been
non-adherent or undertreated; the weak association
between NfL and NCC supports this. Another possibility
is that ongoing neuroaxonal injury in chronically-treated
patients does not solely depend on circulating copper
levels; ATP7B is widely expressed in the brain,16 therefore
dysfunctional intracellular copper handling within neu-
rons might also influence neuronal vulnerability.
TABLE 1. Group demographic and clinical characteristics, copper indices and biomarker results
Characteristic Control (n = 38) Hepatic (n = 17) Neurologic (n = 23) P a P b P c
Age (y) (mean (SD)) 44 (13) 42 (15) 44 (14) 0.83 0.77 0.47
Sex (female) (n (%)) 24 (63) 8 (47) 12 (52) 0.38 0.75 0.15
Disease duration (y) (mean (SD)) 20 (15)d 25 (16)d 0.37 0.56
Active disease status (n (%)) 0 (0) 5 (22)
KF rings present (n (%)) 3 (23)e 14 (64)e
Evidence of cirrhosis (n (%)) 7 (41)f 10 (43)f
Treatments (n (%))
Penicillamine 9 (53) 17 (74)
Trientine 5 (29) 4 (17)
Zinc 1 (6) 0 (0)
Combination 0 (0) 1 (4)
Transplant 2 (12) 1 (4)
UWDRS (median (IQR))
UWDRS-N 3 (0–4) 22 (14–37)
UWDRS-P 8 (3–13) 8 (4–15)
UWDRS-F 0 (0–1) 3 (2–9)
Copper indices (median (IQR))
NCC (μmol/L) 1.7 (1.4–2.3) 1.7 (1.4–2.6) 0.86 0.54
CuEXC (μmol/L) 0.6 (0.4–0.6) 0.5 (0.3–0.8) 0.71 0.13
UCu (μmol/24 h) 4.2 (1.7–7.7) 5.0 (3.6–7.3) 0.28 <0.001
Biomarkers (median (IQR))
NfL (ng/L) 7.6 (5.4–9.9) 7.0 (4.9–8.8) 8.7 (6.6–16.0) 0.005 0.005 0.048
Tau (ng/L) 1.4 (1.1–2.3) 1.4 (1.3–1.7) 1.8 (1.2–2.1) 0.57 0.13 0.57
GFAP (ng/L) 84 (65–136) 80 (67–90) 84 (65–136) 0.61 0.50 0.42
UCH-L1 (ng/L) 23 (14–41) 23 (17–31) 23 (14–41) 0.014 0.06 0.87
Abbreviations: SD, standard deviation; KF, Kayser–Fleischer; IQR, interquartile range; UWDRS, Unified Wilson’s Disease Rating Scale; -N, neurological examina-
tion subscore; -P, psychiatric subscore; -F, function subscore; NCC, non-ceruloplasmin-bound copper; CuEXC, exchangeable copper; UCu, urine copper;
NfL, neurofilament light; GFAP, glial fibrillary acidic protein; UCH-L1, ubiquitin carboxyl terminal hydrolase-L1.
a
P values when comparing neurological and control groups.
b
P values when comparing neurological and hepatic groups.
c
P values when comparing active and stable patients.
dDisease duration refers to symptom onset; six asymptomatic patients identified by family screening are excluded.
eFour patients with hepatic and one patient with neurological presentations who were unable to have slit lamp examination and did not have Kayser–Fleischer
rings at the bedside are excluded.
fEvidence of cirrhosis determined by previous imaging and histopathology results. One participant had features of decompensated liver disease (ascites) during
their research visit.
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Importantly, NfL increases with age and age-specific
reference ranges are not yet available.9 Group differences
were clearer when evaluated with linear regression than
with ROC curve analysis because age was a covariate,
and our cohort included older adults. NfL may detect
neurological involvement at initial presentation with
greater sensitivity and specificity than our results suggest
given WD usually presents in adolescence or early adult-
hood. Evidence from a cohort of presymptomatic
patients with Huntington’s disease indicates that NfL is
a highly sensitive marker of neurodegeneration in young
people; concentrations in plasma increased approxi-
mately 24 years before predicted disease onset.17
The association of tau and UCH-L1 with UWDRS
subscores in the absence of differences between active
and stable patients suggests these reflect more chronic
neurological involvement. The lack of association
between GFAP, a glial-specific protein, and UWDRS
subscores suggests that reactive gliosis is not prominent
in chronically-treated patients.
The small size of our cohort, specifically the inclusion
of only five patients with active disease, is the main lim-
itation of this study: any lack of differences should be
interpreted with care. The next step is to study our
cohort prospectively. NfL will also need to be investi-
gated in larger, independent cohorts of recently-
diagnosed patients or as an exploratory outcome mea-
sure in clinical trials for WD.
Our findings may have important implications for WD
monitoring given neurological disease activity is currently
determined by examination alone.5 Unlike most neurode-
generative diseases, treatments affecting disease course are
already established in WD, and the introduction of novel
monitoring approaches could improve neurological out-
comes in the short term. We predict a role for NfL in
monitoring both “de-coppering” and maintenance phases
of WD treatment. NfL might help identify which treat-
ments and doses optimize neurological recovery and indi-
cate paradoxical worsening.
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ABSTRACT: Background: The ataxin-2 (ATXN2)
gene contains a cytosine-adenine-guanine repeat
sequence ranging from 13 to 31 repeats, but when sur-
passing certain thresholds causes neurodegeneration.
Genetic alterations in ATXN2 other than pathological
cytosine adenine guanine (CAG) repeats are unknown.
Methods/Results: We have identified a 9–base pair
duplication in the 2-gene ATXN2 sense/antisense
region. The duplication was found in a Swedish family
with spinocerebellar ataxia 3 with parkinsonism, con-
ferring a deviated age at onset unexplained by the
concomitant presence of ATXN2 intermediate alleles.
Similarly, C9ORF72 amyotrophic lateral sclerosis
cases bearing the same duplication had earlier age at
onset than those with C9ORF72 and ATXN2 interme-
diate alleles. No effect was evident in Parkinson’s dis-
ease (PD) cases without known PD gene mutations.
Conclusions: We describe the first genetic alteration
other than the known intermediate-range CAG repeats
in ATXN2. This 9–base pair duplication may act as an
additional hit among carriers of pathological nucleotide
expansions in ATXN3 and C9ORF72 with ATXN2 inter-
mediate. © 2020 The Authors. Movement Disorders
published by Wiley Periodicals LLC on behalf of Inter-
national Parkinson andMovement Disorder Society.
Key Words: ATXN2; SCA3; Parkinson’s disease;
C9ORF72; genemodifier; genotype–phenotypecorrelations
The ataxin-2 gene (ATXN2) contains a cytosine-
adenine-guanine (CAG) repeat sequence in exon 1. The
normal length of CAG repeats ranges from 13 to
31 repeats. Intermediate repeats between 27 and
31 CAG repeats are associated with neurological dis-
eases, and expansions beyond 34 CAG repeats cause
spinocerebellar ataxia 2 (SCA2).1-4
Genetic alterations of ATXN2 other than pathologi-
cal CAG repeats are unknown. We identified a 9–base
pair (bp) duplication in the ATXN2 promoter/exon
1 region lowering age at onset (AO) for spinocerebellar
ataxia 3/Machado Joseph disease (SCA3/MJD) and
C9ORF72-amyotrophic lateral sclerosis (ALS).
Material and Methods
Details on Material and Methods are presented as
supplementary material (Figs. 1A and S1, Tables S1
and S2).
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